Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022


The Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 report provides comprehensive understanding and unprecedented access to the monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
June 2022
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.


This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:


  • Monoclonal antibodies
    • Murine mAb
    • Chimeric mAb
    • Humanized mAb
    • Human aAb


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2015, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.


The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms.


Chapter 3 provides a review of the leading monoclonal antibody deals since 2015. Deals are listed by headline value, signed by big pharma, most active monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.


Chapter 5 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2015. The chapter is organized by specific monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type definitions and monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody partnering and dealmaking since 2015.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.


Key benefits


Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 provides the reader with the following key benefits:


  • In-depth understanding of monoclonal antibodies deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of monoclonal antibodies agreements 
  • Comprehensive access to over 1000 actual monoclonal antibodies deals entered into by the world’s biopharma companies
  • Identify the leading monoclonal antibody partnering companies
  • Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 is intended to provide the reader with an in- depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.


Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 includes:


o  Trends in monoclonal antibody dealmaking in the biopharma industry since 2015

o  Access to headline, upfront, milestone and royalty data

o  Access to over 1000 monoclonal antibody deal records

o  The leading monoclonal antibody deals by value since 2015

o  Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2015


In Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022, the available deals are listed by:


o  Company A-Z

o  Headline value

o  Stage of development at signing

o  Deal component type

o  Monoclonal antibodies type


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 report provides comprehensive access to available deals and contract documents for over 1000 monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:


  • What are the precise monoclonal antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Monoclonal Antibody Partnering Terms and Agreements 2015 to 2022 provides the reader with the following key benefits:


  • In-depth understanding of monoclonal antibody deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Acces to the structure of monoclonal antibody agreements
  • Comprehensive access to over 1000 actual monoclonal antibody deals entered into by the world’s biopharma companies, together with real world clause examples
  • Full listing of monoclonal antibody deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading monoclonal antibody deals by value since 2015
  • Identify the most active monoclonal antibody dealmakers since 2015
  • Insight into the terms included in a monoclonal antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in monoclonal antibody dealmaking


2.1. Introduction
2.2. Monoclonal antibody partnering over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody partnering by deal type
2.5. Monoclonal antibody partnering by therapy area
2.6. Deal terms for monoclonal antibody partnering
2.6.1 Monoclonal antibody partnering headline values
2.6.2 Monoclonal antibody deal upfront payments
2.6.3 Monoclonal antibody deal milestone payments
2.6.4 Monoclonal antibody royalty rates


Chapter 3 – Leading monoclonal antibody deals


3.1. Introduction
3.2. Top monoclonal antibody deals by value


Chapter 4 – Most active monoclonal antibody dealmakers


4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody partnering company profiles


Chapter 5 – Monoclonal antibody contracts dealmaking directory


5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory


Chapter 6 – Monoclonal antibody dealmaking by technology type


Monoclonal antibodies
Chimeric mAb
Humanized mAb
Human mAb
Murine mAb


Appendix 1 – Monoclonal antibody deals by company A-Z

Appendix 2 – Monoclonal antibody deals by stage of development

Appendix 3 – Monoclonal antibody deals by deal type

Appendix 4 – Monoclonal antibody deals by therapy area

Appendix 5 – Deal type definitions

Appendix 6 – Further reading

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures


Figure 1: Therapeutic antibody definitions
Figure 2: Monoclonal antibody partnering since 2015
Figure 3: Active monoclonal antibody dealmaking activity since 2015
Figure 4: Monoclonal antibody partnering by deal type since 2015
Figure 5: Monoclonal antibody partnering by disease type since 2015
Figure 6: Monoclonal antibody deals with a headline value
Figure 7: Monoclonal antibody deals with an upfront value
Figure 8: Monoclonal antibody deals with a milestone value
Figure 9: Monoclonal antibody deals with a royalty rate value
Figure 10: Top monoclonal antibody deals by value since 2015
Figure 11: Most active monoclonal antibody dealmakers since 2015

Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,995: single site license
  • $17,995: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3D Medicines, 3rd People’s Hospital of Shenzhen, 3SBio, 4D Pharma, 9 Meters Biopharma, A*STAR Bioprocessing Technology Institute, Abbvie, Abcam, AbCellera, AbCheck, AbClon, Abdul Latif Jameel Health, ABL Bio, Ablexis, Ablynx, Abmuno Therapeutics, Aboundbio, Abpro, Ab Studio, Abveris, Abzena, Acceleron Pharma, Accord Healthcare, Acerta Pharma, Achaogen, Acticor Biotech, Adagene, Adagio Therapeutics, Adaptimmune, Adaptive Biotechnologies, Adimab, Adium Pharma, Adlai Nortye, Aduro BioTech, Advanced BioScience Laboratories, Advaxis, Aeglea BioTherapeutics, Aevi Genomic Medicine, AffaMed Therapeutics, Affimed Therapeutics, Affinita Biotech, AGC Biologics, Agenus Bio, Agilvax, Aimmune Therapeutics, Ajinomoto, Ajinomoto Bio-Pharma Services, Akeso Biopharma, Alder Biopharmaceuticals, Alector, Alexion Pharmaceuticals, Alfasigma, AlivaMab Discovery Services, Allergan, Alligator Bioscience, Allinaire Therapeutic, Alloy Therapeutics, Almac Group, Almirall, Alphamab Biopharmaceuticals, Alpine Immune Sciences, Alvogen, Alvotech, ALX Oncology, Alzheimer's Drug Discovery Foundation, Ambrx, Amgen, Amneal Pharmaceuticals, Amplyx Pharmaceuticals, AnGes MG, Angios, Antengene, Antidote Therapeutics, Antigen Express, Antitope, Apceth, Aperion Biologics, Apexigen, Applied BioMath, APRINOIA Therapeutics, Aptevo Therapeutics, Aqualung Therapeutics, Arch Oncology, Arcus Biosciences, arGEN-X, argenx, Aridis Pharmaceuticals, ARMO Biosciences, Array Biopharma, Arsanis Biosciences, Ascenion, Ascentage Pharma, Asieris MediTech, Aslan Pharma, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Atara Biotherapeutics, Athenex, Atlab Pharma, Atlante Biotech, Atlas Antibodies, ATP, Atreca, ATUM, aTyr Pharma, Augmenta, Aulos Bioscience, AvantGen, Avantor, AVEO Oncology, Avid Bioservices, Avidity Biosciences, Axantia, Aytu BioPharma, Back-A-Line, Banner Alzheimer's Institute, Basilea Pharmaceutica, Bausch & Lomb, Bavarian Nordic, Baxalta, Bayer, Baylor Institute for Immunology Research, BB100, BeiGene, Beijing InnoCare Pharma, BerGenBio, Berkeley Lights, Betta Pharmaceuticals, BHR Pharma, Bill and Melinda Gates Foundation, Binex, Bio-Manguinhos/Fiocruz, Bio-Thera Solutions, BioArctic Neuroscience, BioAtla, Biocare Medical, Biocon, Biocytogen, Biodesix, Bioeq IP, Bio Farma, Biogen, BioInvent, BiolineRX, Biolojic Design, BioMarker Strategies, Biomedical Advanced Research and Development Authority, Biomm, Biomunex Pharmaceuticals, Bioncotech Therapeutics, Biond Biologics, BioNTech, BioRap Technologies, BiosanaPharma, Biosion, Biothera Pharmaceuticals, Biotools, BioVectra, BioXcel, Blackstone, BliNK Biomedical, BliNK Therapeutics, Bluebird Bio, BlueJay Therapeutics, Boehringer Ingelheim, Bolt Biotherapeutics, Boston Immune Technologies and Therapeutics, Bpifrance, BridgeBio Pharma, Brigham and Women's Hospital, Bright Peak Therapeutics, Brii Biosciences, Bristol-Myers Squibb, C-Bridge Capital, C2N Diagnostics, Caelum Biosciences, California Institute for Regenerative Medicine, Calithera Biosciences, Calypso Biotech, Cancer Australia, Cancer Focus Fund, Cancer Prevention and Research Institute of Texas, Cancer Research Technology, Cancer Research UK, CanCure, Candel Therapeutics, Cantargia, Care Access Research, Caris Life Sciences, Catalent, CBT Pharmaceuticals, CDI Laboratories, Cedars-Sinai Medical Center, Celexion, Celgene, Celiac Disease Foundation, Celimmune, Celldex Therapeutics, Cellectis, Cell Signaling Technology, Celltrion, Celsius Therapeutics, Celularity, Cenexi, Centre for Drug Research and Development (CDRD), CG Oncology, Champions Oncology, Checkmate Pharmaceuticals, Checkpoint Therapeutics, Chi-Med, Chiesi Farmaceutici, Chime Biologics, Chiome Bioscience, Chugai Pharmaceutical, Cilag AG, Cipla, City of Hope, City of Hope Comprehensive Cancer Center, Clinical Trial and Consulting Services, Clinica Universidad Navarra, Clinigen, Clovis Oncology, CMAB Biopharma, CMC Biologics, Coherus Biosciences, Cold Genesys, Columbia University, Complement Pharma, Compugen, Conagen, Convergent Therapeutics, Corvidia Therapeutics, Corvus Pharmaceuticals, Covalab, Creative Biolabs, Crescendo Biologics, Cromos Pharma, Crown Bioscience, CR Pharma, Crystal Bioscience, CSL, CSPC Pharmaceutical Group, CStone Pharmaceuticals, Cue Biopharma, Cullinan Oncology, Curant Health, Curative Biotechnology, Cure Duchenne, CureVac, Cytodyn, Cytovation, Daiichi Sankyo, Dako, Debiopharm, Defense Advanced Research Projects Agency, Denali Therapeutics, DendroCyte, Department of Defense, Department of Health and Human Services, Dermira, Diagnostic International Distribution, Diaprost, Disc Medicine, Distributed Bio, DNAtrix, Dong-A ST, Dr. Reddy's Laboratories, Duke University, Dyadic International, Dynavax Technologies, E25Bio, EA Pharma, eFFECTOR Therapeutics, EirGenix, Eisai, Elanco, Elektrofi, Elevation Oncology, Eleven Biotherapeutics, Eli Lilly, ElsaLys Biotech, EluSys Therapeutics, EMD Millipore, EMD Serono, Emergent BioSolutions, Enthera, Enumeral Biomedical, Enzene Biosciences, Enzolytics, Epirus Biopharmaceuticals, EpiThany, EQRx, Equillium, Erasmus University Medical Center, EsoCap, Essex Bio-Technology, Eucure Biopharma, Eureka Therapeutics, Eurofarma, European Union, European Union Regional Development Fund, EUSA Pharma, Eutilex, Evaxion Biotech, Everest Medicines, Eversana, Evotec, ExCEEd Orphan, Exelixis, F-Star Therapeutics, FairJourney Biologics, FarmaMondo Group, Faron Pharmaceuticals, Fate Therapeutics, Ferring Pharmaceuticals, Five Prime Therapeutics, FLX Bio, Food and Drug Administration (FDA), Formosa Pharmaceuticals, Forty Seven, Fosun Kite Biotechnology, Foundery Innovations, Fred Hutchinson Cancer Research Center, Fresenius Kabi Pharmaceuticals, Fuhong Hanlin, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, Fusion Pharmaceuticals, Galapagos, Galaxy Biotech, Galderma, Galecto, Genagon Therapeutics, Genentech, Generation Biotech, Genexine, Genmab, Gennao Bio, Genome and Company, Genor Biopharma, Genprex, GenScript Biotech, GenScript ProBio, Georgetown University, Gilead Sciences, GlaxoSmithKline, Glenmark Pharmaceuticals, Global Blood Therapeutics, Glycocept, Glycotope Biotechnology, Glythera, Goldfinch Bio, Goodwin Biotechnology, Gossamer Bio, Government of Canada, Government of Singapore, Gradalis, Gritstone Bio, GTP Technology, H-Immune, H3 Biomedicine, Hadasit Bioholdings, HaemaLogiX, Halozyme Therapeutics, HanAll Pharmaceuticals, Harbour Antibodies, Harbour Biomed, Harvard Pilgrim Health Care, Heidelberg Pharma, Henlius Biotech, HiberCell, HiFiBio, Highlight Therapeutics, High Line Bio, Hikma Pharmaceuticals, Hisun BioRay, Hoffmann La Roche, Hookipa Pharma, Hope Medicine, Horizon Discovery, Horizon Therapeutics, Hospira, Huadong Medicine, Hualan Genetic, Humabs BioMed, Humanigen, Hummingbird Bioscience, Hutchison MediPharma, Huyabio International, I-mab, i2 Pharmaceuticals, iBio, Icahn School of Medicine at Mount Sinai, IcanoMAB, Ichnos Sciences, Ichor Medical Systems, Iconic Therapeutics, IDBiologics, iDD Biotech, Idera Pharmaceuticals, Igyxos, ImCheck Therapeutics, ImClone Systems, Immatics Biotechnologies, Immix Biopharma, ImmuneCyte Life Sciences, Immune Design, ImmuneOncia Therapeutics, Immune Pharmaceuticals, ImmuNext, Immunitas Therapeutics, ImmunoBrain Checkpoint, ImmunoChina Pharmaceuticals, Immunocore, ImmunoGen, Immunome, Immunomedics, Immunomic, ImmunoPrecise Antibodies, Immunovaccine, Immutep, IMPACT Therapeutics, Imugene, IMV, Incyte, InDevR, Indiana University, Indian Institute of Science Education and Research, Infex Therapeutics, Infinity Pharmaceuticals, InflamaCORE, Inhalon Biopharma, Initium Therapeutics, Innate Pharma, Innovate UK, Innovent Biologics, Inovio, Inovio Pharmaceuticals, Inserm, Inserm Transfert, Inspirna, Institut Bergonie, Institut Curie, Institute for Basic Science, Institute of Biophysics, Institut Pasteur, Intarcia Therapeutics, Intas Pharmaceuticals, Integral Molecular, INTELLiSTEM, Intensity Therapeutics, International Consortium on Anti-Virals, IntoCell, Intract Pharma, Invenra, Invetx, InxMed, IO Biotech, Ionova, IONTAS, Ipsen, IRBM, ISA Pharmaceuticals, Isotopia Molecular Imaging, Israel Institute for Biological Research, Italian Association for the Study of Pancreas, iTeos Therapeutics, Izana Bioscience, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Janssen Sciences, Jasper Therapeutics, Jazz Pharmaceuticals, JHL Biotech, Jiangsu Alphamab, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu Hengrui Pharmaceuticals, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Johnson Matthey, Jounce Therapeutics, Juno Therapeutics, Junshi Biosciences, Just Biotherapeutics, Juvenile Diabetes Research Foundation, Kadmon Pharmaceuticals, KAHR Medical, Kalbe Genexine Biologics, KBI BioPharma, Kelun-Biotech Biopharmaceutical, Kennedy Institute of Rheumatology, Kiadis Pharma, Kindred Bio, Kiniksa Pharmaceuticals, Kintor, Kite Pharma, Kitov Pharma, Kleo Pharmaceuticals, Kodiak Sciences, Kolltan Pharmaceuticals, KPM Tech, Kymab, Kyowa Hakko Kirin, Kyttaro, Laboratoires Thea, LA Cell, Laekna, LakePharma, Lassen Therapeutics, Leads Biolabs, Leap Therapeutics, Lee's Pharmaceutical, Leica Biosystems, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, LG Life Sciences, Libbs Farmaceutica, LifeArc, Ligand Pharmaceuticals, Linnaeus Therapeutics, Liverpool School of Tropical Medicine, Livzon Mabpharm, Lobesity Pharma, Lonza, Lumos Pharma, Lupagen, Lupus Therapeutics, Lyvgen Biopharma, MAB Discovery, Mabion, MabQuest, MAbSilico, mAbsolve, Mabspace Bioscience, MabVax Therapeutics, mAbXience, Mabylon, Macquarie University, Macrogenics, Magenta Therapeutics, MAIA Biotechnology, Manhattan BioSolutions, Mapp Biopharmaceutical, Massachusetts General Hospital, Matrix Medical Network, Mayo Clinic, MD Anderson Cancer Center, Medgenics, Medicago, Medical Research Council, Medigen Biotechnology, Medimabs, MedImmune, Mediolanum, Meiji Seika, Memorial Sloan Kettering Cancer Center, Memo Therapeutics, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Mereo BioPharma, Merrimack Pharmaceuticals, Merus, MicroConstants, Minomic, Mitra Biotech, Mitsubishi Tanabe Pharma, ModiQuest Research, Molcure, Moleculin Biotech, MolMed, Momenta Pharmaceuticals, Monopar Therapeutics, MoonLake Immunotherapeutics, MorphoSys, Morphotek, Mount Sinai Health System, MSD, Mundipharma, Mustang Bio, Mylan Laboratories, Mylan Pharmaceuticals, Myriad Genetics, myTomorrows, NantBioScience, NantCell, Nantes University, NantKwest, Nantong Jinghua Pharmaceutical, NantWorks, Nanyang Technological University, Nascent Biotech, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Center for Tumor Diseases, National Comprehensive Cancer Network (NCCN), National Heart, Lung and Blood Institute, National Institute for Bioprocessing Research and Training, National Institute of Allergy and Infectious Diseases, National Institute of Standards and Technology, National Institute on Aging, National Institutes of Health, National University Cancer Institute, Navrogen, NCIC Clinical Trials Group, Nectin Therapeutics, Nektar Therapeutics, Nelum Pharma, NeoBiotechnologies, NeoImmuneTech, Neoleukin Therapeutics, Neon Therapeutics, NETRIS Pharma, Neurimmune Therapeutics, Neuroblastoma and Medulloblastoma Translational Research, Newsummit Biopharma, Neximmune, Nexvet, NGM Biopharmaceuticals, Nkarta Therapeutics, NKMax America, Nordic Society of Gynaecological Oncology, Northern Biologics, NorthStar Medical Radioisotopes, Northwestern University, Novadiscovery, NovalGen, NovaRock Biotherapeutics, Novartis, Novasep, Novelogics Biotechnology, Novelty Nobility, NovImmune, Novocure, Novo Nordisk, Noxopharm, Noxxon Pharma, Numab, OBI Pharma, Olivia Newton-John Cancer Research Institute, Ology Bioservices, Olympic Protein Technologies, Omeros, OncoCare Therapeutics, OncoImmune, Oncologie, Oncolytics Biotech, OncoMed Pharmaceuticals, OncoQuest, OncoSec Medical, Oncothyreon, Oncternal Therapeutics, Oncurious, OncXerna Therapeutics, Ono Pharmaceutical, Open Monoclonal Technology, Orsini Healthcare Specialty Pharmacy, OSE Immunotherapeutics, Otsuka, Oxford BioTherapeutics, Pall Corporation, Panacea Pharmaceuticals, Pandion Therapeutics, Panorama Research, Parexel Biotech, Pascal Biosciences, Patheon, PATH Malaria Vaccine Initiative, PDS Biotechnology, Pelican Therapeutics, Peregrine Pharmaceuticals, Perelman School of Medicine, Perrigo, Personal Genome Diagnostics, Personalis, Pfenex, Pfizer, Phanes Therapeutics, PharmAbcine, Pharmapark, PhaseBio Pharmaceuticals, Pierre Fabre, Pionyr Immunotherapeutics, PlantForm, PlantPraxis Biotecnologia, Pneuma Respiratory, POINT Biopharma, Polpharma, Portal Instruments, Poseida Therapeutics, Potenza Therapeutics, Precision Biologics, Precision BioSciences, Prellis Biologics, Prestige BioPharma, Probiodrug, ProBioGen, ProciseDx, Progenetics, Progenics Pharmaceuticals, Promega, Prothena Biosciences, ProtoKinetix, Provention Bio, PT Etana Biotechnologies, PULSALYS, PureTech Health, Purolite, Pyxis Oncology, Q32 Bio, QBiotics, Qiagen, Q Therapeutics, Quantum Leap Health Care Collaborative, Queensland Institute of Medical Research (QIMR), Quest PharmaTech, Qurient, R-Pharm, Radboud University Nijmegen Medical Centre, Rakuten Medical, RefleXion Medical, Regeneron Pharmaceuticals, Regenxbio, Regnum, Releviate Therapeutics, Rentschler Biotechnologie, Repligen, Replimune, Rexahn Pharmaceuticals, Rezolute, Ridgeback Biotherapeutics, River Vision Development, Roche, Rockefeller University, Rocket Pharmaceuticals, Roivant Sciences, Roswell Park Cancer Institute, Royalty Pharma, RQ Biotechnology, RubrYc Therapeutics, SAB Biotherapeutics, SAB Therapeutics, Saccharo, Samsung Bioepis, Samsung Biologics, Samyang Biopharmaceuticals, San Diego Biomedical Research Institute, Sandoz, Sanofi, Sanofi-Aventis, Sanofi-Pasteur, Sarah Cannon Research Institute, SATT Sud-Est, Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), SaudiVax, Scandion Oncology, Schrodinger, SciClone Pharmaceuticals, SciNeuro Pharmaceuticals, Scripps Research Institute, Sea Lane Biotechnologies, Seattle Genetics, Seismic Bio, Selecxine, Selexis, SELLAS Life Sciences Group, Sensei Biotherapeutics, Serum Institute of India, Seven and Eight Biopharmaceuticals, SevenScore Pharmaceuticals, Sevion Therapeutics, SFJ Pharmaceuticals, Shandong Fontacea Pharmaceutical, Sharp HealthCare, Shenogen Pharma, Shenzhen Arimab Biopharmaceuticals, Shenzhen Chipscreen Biosciences, Shenzhen Hepalink Pharmaceutical, Shionogi, Shire Pharmaceuticals, Silverback Therapeutics, Simcere Pharmaceuticals, Simon Fraser University, Sinopharm, Sirnaomics, Sorrento Therapeutics, Sosei Heptares, SOTIO, Spanish National Research Council, Specialized Medical Services-oncology, Spring Bank Pharmaceuticals, STADA Arzneimittel, Stand Up To Cancer, Stanford University, Strata Oncology, Sud Investments, Sun Pharmaceutical, Surface Oncology, Swedish Orphan, Swedish Orphan Biovitrum, Swiss Federal Funding Programme, Swixx Biopharma, Symphogen, Syndax Pharmaceuticals, Syngene International, Synlogic, Syracuse University, Syros Pharmaceuticals, T-Cure Bioscience, Taiho, Takeda Pharmaceutical, Talem Therapeutics, Tanabe Research Laboratories, TARIS Biomedical, Tavotek Biotherapeutics, TCR2 Therapeutics, Telcon RF Pharmaceuticals, Telix Pharmaceuticals, Tempest Therapeutics, TeneoBio, Tesaro, Tessa Therapeutics, Tetragenetics, TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries, TFF Pharmaceuticals, TG Therapeutics, The International AIDS Vaccine Initiative, Theradiag, Theramex, Theranyx, Theravectys, Thermo Fisher Scientific, ThromboGenics, TILT Biotherapeutics, Tiziana Life Sciences, Tizona Therapeutics, Tmunity Therapeutics, TONIX Pharmaceuticals, Torque Therapeutics, TOT BIOPHARM, TPG Capital, TRACON Pharmaceuticals, TransBio, Transcenta, Transgene, TransPerfect Life Sciences, Transporin, TransThera, Tri-Institutional Therapeutics Discovery Institute, TrialSpark, Trianni, Trieza Therapeutics, Trinomab Biotech, Trio Pharmaceuticals, TSB Therapeutics, Tsinghua University, Turgut Ilaclari, Twist Bioscience, UbiVac, UCB, Ultragenyx Pharmaceuticals, UMass Memorial Medical Center, Unilife, UnitedHealth, Universite Claude Bernard Lyon, University College London, University of Bergen, University of Birmingham, University of British Columbia, University of California, San Diego, University of California Los Angeles, University of California Riverside, University of California San Francisco, University of Cologne, University of Maryland Baltimore, University of Massachusetts Medical School, University of Melbourne, University of Minnesota, University of New Mexico, University of Nottingham, University of Oxford, University of Pennsylvania, University of Texas, University of Wisconsin Carbone Cancer Center (UWCCC), Unum Therapeutics, Upadia, Uppsala University, UroGen Pharma, US Army Medical Research and Material Command, US Army Medical Research Institute of Infectious Diseases, US Government, Utrecht University, Vaccinex, Valeant Pharmaceuticals, ValenzaBio, Valneva, Vanderbilt University, Vaximm, Vcell Healthcare, Vect-Horus, Vedanta Biosciences, Velabs Therapeutics, Verastem, Verseau Therapeutics, VIB, Vical, Viela Bio, Vinnova, Viralytics, Vir Biotechnology, Viroclinics Biosciences, Visterra, Vitaeris, Voyager Therapeutics, Vyera Pharmaceuticals, Vyriad, Werewolf Therapeutics, Wilex, WindMIL Therapeutics, Wistar Institute, World Health Organization, WuXi Biologics, Wuxi Shuangliang Biotechnology, XBiotech, Xbrane Bioscience, xCella Biosciences, Xencor, Xilio Therapeutics, Xoma, Y-Biologics, Y-mAbs Therapeutics, Yale University, Yas Holding, Yissum Research Development, ZAI Laboratory, Zenoaq, Zhejiang Bossan Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Huahai Pharmaceutical, Zoetis, Zumutor Biologics, Zydus Cadila, Zymeworks, ZyVersa Therapeutics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.